Venture capitalists ride biotech wave one drug at a time

April 10, 2015 12:41 PM

69 0

LONDON, April 10 (Reuters) - How many people does it take to run a successful biotech company? Just two, judging by the sale of XO1, a one-drug British firm snapped up last month by Johnson & Johnson.

Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins.

Read more

To category page